ReviewMolecular psychiatry2022
A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings.
Review in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05487885 (Anhedonia, Development, and Emotions), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- From Neural Circuits to Behavior: Examining the Central Role of Anhedonia in Major Depression.Advances in experimental medicine and biology · 2026Review
- The cognitive neuroscience of ketamine in major depression.Brain : a journal of neurology · 2025Review
- A nonlinear relationship between prediction errors and learning rates in human reinforcement-learning.PLoS computational biology · 2025Article
- Opioid Regulation of Social Homeostasis: Connecting Loneliness to Addiction.Biological psychiatry · 2025Review
- Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens.Neuron · 2025Article
- Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.The international journal of neuropsychopharmacology · 2025Review
- Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.Molecular psychiatry · 2024Review
- Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.Brain and behavior · 2024Article
- Article
- A novel framework for ketamine-assisted couple therapy.Frontiers in psychiatry · 2024Review
- Chemogenetics identifies separate area 25 brain circuits involved in anhedonia and anxiety in marmosets.Science translational medicine · 2023Article
- A unified model of ketamine's dissociative and psychedelic properties.Journal of psychopharmacology (Oxford, England) · 2023Review
- C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.Brain, behavior, and immunity · 2022Article
- Review
- Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?The American journal of psychiatry · 2022Review
- Negative symptoms in alcohol use disorder: A pilot study applying the two-factor model of negative symptoms to patients with alcohol use disorder.Frontiers in psychiatry · 2022Article
- Habenular Involvement in Response to Subcallosal Cingulate Deep Brain Stimulation for Depression.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Anhedonia, a pronounced reduction in interest or pleasure in any of life's daily activities, is a cardinal symptom of major depression. In this Perspective article, we synthesise the recent evidence from rodent, monkey and human neuroimaging literature to highlight how the habenula, a small evolutionarily conserved subcortical structure located in the midbrain, may orchestrate the behavioural expression of anhedonia across fronto-mesolimbic networks. We then review how this circuitry can be modulated by ketamine, an NMDA receptor antagonist with rapid antidepressant properties. We propose that experimental paradigms founded in reinforcement learning and value-based decision-making can usefully probe this network and thereby help elucidate the mechanisms underlying ketamine's rapid antidepressant action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.